Fortress Biotech retires $15M Oaktree debt as quarterly revenue edges up 9%
The company ended the third quarter without its Oaktree borrowing, reporting a $7.9M loss on $19.2M of sales, mostly from Journey Medical's Emrosi.
Fortress Biotech has removed one of its main debt obligations from the balance sheet. In September it paid the last $15M owed under its credit facility with Oaktree, the company said as it published third-quarter 2026 results on 13 November.
Revenue for the quarter was $19.2M, a 9% increase. Most of it came from Emrosi, which is sold by Fortress's subsidiary Journey Medical. The company still made a loss: $7.9M was attributed to common stockholders. The information available does not break out Emrosi sales or give comparative figures beyond the 9% growth rate.
On the pipeline, a Fortress subsidiary has licensed FB-607 from Cedars-Sinai. The candidate is being developed for irritable bowel syndrome with diarrhoea (IBS-D) and is in Phase 2. Licence terms and development timelines were not disclosed in the material reviewed, so the deal's cost and the candidate's path to market are unclear.
Fortress also pointed to progress at partner companies. Japan approved anselamimab in September for systemic kappa light chain amyloidosis. Separately, Crystalys closed a $130M Series B financing to support dotinurad in gout. No regulatory status for dotinurad was provided.
Why it matters
- Repaying the Oaktree facility leaves Fortress without that $15M borrowing, though the company is still loss-making.
- Emrosi accounts for most of the revenue, so Journey Medical's commercial execution largely determines the top line.
- FB-607 is a Phase 2 in-licensing for IBS-D. It is early-stage, and the licence terms were not disclosed.
- Partner milestones, the Japanese approval of anselamimab and Crystalys's $130M raise for dotinurad, widen the story beyond the company's own products.
Company's press release (SEC filing): Fortress Biotech, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
